BRIEF published on 06/14/2024 at 22:50, 1 year 9 months ago Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase® Shareholders Theralase® Virtual Meeting AGSM Zoom Presentation
PRESS RELEASE published on 06/14/2024 at 22:45, 1 year 9 months ago Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R) Theralase Technologies Inc. provides a reminder for its Annual General and Special Meeting to be held on June 19th, 2024, with a virtual Zoom presentation including a Q&A session for shareholders Annual General Meeting Shareholders Theralase Technologies Inc. AGSM Virtual Zoom Presentation
BRIEF published on 06/12/2024 at 13:05, 1 year 9 months ago Rutherrin® Increases Efficacy of Chemotherapy Cancer Treatment Chemotherapy Rutherrin® Multidrug Resistance Theralase® Technologies
PRESS RELEASE published on 06/12/2024 at 13:00, 1 year 9 months ago Rutherrin(R) Increases Efficacy of Chemotherapy Theralase Technologies announces preclinical success of Rutherrin® in enhancing chemotherapy efficacy and reducing multidrug resistance in cancer cells Cancer Treatment Theralase Technologies Rutherrin® Multidrug Resistance Chemotherapy Efficacy
BRIEF published on 06/10/2024 at 13:05, 1 year 9 months ago Ruvidar(TM) Enhances Efficacy of Cancer Drug Cancer Treatment Theralase Technologies Ruvidar(TM) BCG NMIBC
PRESS RELEASE published on 06/10/2024 at 13:00, 1 year 9 months ago Ruvidar(TM) Enhances Efficacy of Cancer Drug Theralase® Technologies Inc. announces breakthrough in cancer research by developing RuBCG compound to enhance efficacy of bladder cancer treatment. Preclinical results show promising potential Theralase Technologies Inc. Cancer Research RuBCG Compound Bladder Cancer Treatment Preclinical Results
BRIEF published on 06/06/2024 at 13:05, 1 year 9 months ago Theralase Successfully Destroys Lung Cancer Preclinical Study Theralase Technologies Lung Cancer Rutherrin®
PRESS RELEASE published on 06/06/2024 at 13:00, 1 year 9 months ago Theralase(R) Successfully Destroys Lung Cancer Theralase® Technologies Inc. announces preclinical success with Rutherrin® compound in targeting Non-Small Cell Lung Cancer. Results show improved tumour destruction and slower progression Theralase Technologies Inc. Cancer Treatment Preclinical Study NSCLC Rutherrin Compound
BRIEF published on 06/04/2024 at 13:05, 1 year 9 months ago Theralase® Technology Effective in Virus Inactivation Theralase Ruvidar Antiviral Research Virus Inactivation Heliyon
PRESS RELEASE published on 06/04/2024 at 13:00, 1 year 9 months ago Theralase(R) Technology Effective in Virus Inactivation Theralase Technologies Inc. announces successful inactivation of various viruses with lead compound RuvidarTM through peer-reviewed research. Potential for viral vaccine development highlighted Theralase Technologies Inc. RuvidarTM Peer-Reviewed Research Viral Inactivation Viral Vaccine Development
Published on 03/26/2026 at 00:40, 3 hours 44 minutes ago Challenger RC Resource Upgrade Drilling Complete
Published on 03/26/2026 at 00:30, 3 hours 54 minutes ago Nano One Highlights Recent Objectives & Reports Fourth Quarter 2025 Results
Published on 03/25/2026 at 19:15, 9 hours 9 minutes ago Gemina Laboratories Ltd. Announces Delisting from the CSE
Published on 03/25/2026 at 13:30, 14 hours 54 minutes ago Prince Silver Files NI 43-101 Technical Report for Its Stampede Gap Porphyry Copper-Gold-Molybdenum Project in Nevada
Published on 03/25/2026 at 13:30, 14 hours 54 minutes ago Triera Biosciences - a Zentek Company - Launches Contract Research Organization Services for Custom Aptamer Discovery, Biosensor Enablement, and Machine-Learning Classification
Published on 03/26/2026 at 01:05, 3 hours 19 minutes ago Blokees Announces Upgrade Brand Mission at 2026 Global Partner Conference
Published on 03/25/2026 at 20:00, 8 hours 24 minutes ago Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press
Published on 03/25/2026 at 19:41, 8 hours 43 minutes ago EQS-Adhoc: STRATEC POSTS IMPAIRMENTS, REPORTS PRELIMINARY RESULTS FOR 2025, AND OFFERS GUIDANCE FOR 2026
Published on 03/25/2026 at 19:30, 8 hours 54 minutes ago AIXTRON to expand global footprint with new plant in Malaysia
Published on 03/25/2026 at 19:26, 8 hours 57 minutes ago EQS-Adhoc: AIXTRON SE to expand global footprint with new plant in Malaysia
Published on 03/25/2026 at 18:31, 9 hours 53 minutes ago Strong investment performance and active roll-out of our strategy
Published on 03/25/2026 at 17:45, 10 hours 39 minutes ago Combined General Meeting on May 05, 2026: publication of the notice of Meeting
